BTG is to buy Protherics in stock in a deal that will create one of Britain’s biggest biotech companies. The rationale is to create a ‘sustainably profitable life sciences business’ – one that has the resources to bring drugs to market rather than having to rely on out-licensing deals as is common in the biotech industry.